FY2024 EPS Estimates for Neurogene Raised by HC Wainwright

Neurogene Inc. (NASDAQ:NGNE - Free Report) - HC Wainwright boosted their FY2024 earnings estimates for shares of Neurogene in a report released on Tuesday, November 19th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($4.34) per share for the year, up from their prior estimate of ($4.42). HC Wainwright currently has a "Buy" rating and a $55.00 target price on the stock. The consensus estimate for Neurogene's current full-year earnings is ($4.45) per share. HC Wainwright also issued estimates for Neurogene's Q4 2024 earnings at ($1.05) EPS, Q1 2025 earnings at ($0.77) EPS, Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.83) EPS and FY2025 earnings at ($3.19) EPS.

Other equities research analysts have also issued research reports about the company. Leerink Partners boosted their target price on Neurogene from $45.00 to $72.00 and gave the company an "outperform" rating in a research note on Tuesday, November 12th. BMO Capital Markets lowered their price objective on Neurogene from $60.00 to $45.00 and set an "outperform" rating for the company in a research report on Wednesday. William Blair restated an "outperform" rating on shares of Neurogene in a report on Tuesday. Robert W. Baird upped their price target on shares of Neurogene from $54.00 to $72.00 and gave the company an "outperform" rating in a report on Tuesday, November 12th. Finally, Stifel Nicolaus increased their price target on shares of Neurogene from $44.00 to $60.00 and gave the company a "buy" rating in a research report on Tuesday, November 12th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $60.83.

Neurogene Trading Down 11.0 %

Shares of NASDAQ:NGNE opened at $15.33 on Thursday. The company's fifty day moving average is $45.90 and its 200 day moving average is $39.79. Neurogene has a 52 week low of $12.49 and a 52 week high of $74.49.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new stake in Neurogene in the first quarter worth $120,000. Vanguard Group Inc. boosted its holdings in shares of Neurogene by 906.5% during the 1st quarter. Vanguard Group Inc. now owns 507,483 shares of the company's stock valued at $25,831,000 after buying an additional 457,062 shares in the last quarter. Baker BROS. Advisors LP grew its position in shares of Neurogene by 0.6% in the 1st quarter. Baker BROS. Advisors LP now owns 456,015 shares of the company's stock worth $23,211,000 after buying an additional 2,499 shares during the period. Bank of New York Mellon Corp bought a new position in shares of Neurogene in the 2nd quarter worth about $1,107,000. Finally, Rhumbline Advisers purchased a new position in Neurogene during the 2nd quarter valued at about $491,000. Hedge funds and other institutional investors own 52.37% of the company's stock.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.